Full View

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

S Imbaby, M Ewais, S Essawy… - Human & experimental …, 2014 - journals.sagepub.com
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX–cardiac toxicity is not completely elucidated. The …
被引用次数：72 相关文章

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

S Imbaby, M Ewais, S Essawy… - Human and …, 2014 - ui.adsabs.harvard.edu
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX–cardiac toxicity is not completely elucidated. The …

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats.

S Imbaby, M Ewais, S Essawy… - Human & Experimental …, 2014 - search.ebscohost.com
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX–cardiac toxicity is not completely elucidated. The …

[引用][C] Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

S IMBABY, M EWAIS, S ESSAWY… - Human & experimental …, 2014 - pascal-francis.inist.fr
Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac
toxicity in rats CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

S Imbaby, M Ewais, S Essawy, N Farag - Human & Experimental …, 2014 - hero.epa.gov
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX cardiac toxicity is not completely elucidated. The …

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

S Imbaby, M Ewais, S Essawy, N Farag - Human & Experimental …, 2014 - cir.nii.ac.jp
抄録< jats: p> Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity
is its major dose-limiting factor. Mechanism of DOX–cardiac toxicity is not completely …

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats.

S Imbaby, M Ewais, S Essawy… - Human & Experimental …, 2014 - europepmc.org
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX-cardiac toxicity is not completely elucidated. The …

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

S Imbaby, M Ewais, S Essawy… - Human & experimental …, 2014 - pubmed.ncbi.nlm.nih.gov
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX-cardiac toxicity is not completely elucidated. The …

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats.

S Imbaby, M Ewais, S Essawy, N Farag - 2014 - cabidigitallibrary.org
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX-cardiac toxicity is not completely elucidated. The …
[PDF] researchgate.net

[PDF][PDF] Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

S Imbaby, M Ewais, S Essawy… - Human and Experimental …, 2014 - researchgate.net
Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major
dose-limiting factor. Mechanism of DOX–cardiac toxicity is not completely elucidated. The …